Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Innovent Biologics, Inc. and Eli Lilly & Company | IBI318 | advanced malignancies | Phase I trial initiated enrolling subjects in China |
| TC BioPharm | TCB002 | Acute Myeloid Leukemia (AML) | Phase I trial initiated enrolling 9 subjects in Prague, Czech Republic |
| Innovent Biologics, Inc. | IBI302 | wet age-related macular degeneration (wet AMD) | Phase I trial initiated enrolling 36 subjects |
| Vaxiion Therapeutics, Inc. | VAX014 | non-muscle invasive bladder cancer (NMIBC) | Phase I trial initiated |
| Indalo Therapeutics | IDL-2965 | nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF) | Phase I trial initiated |
| Galapagos NV, MorphoSys AG and Novartis Pharma AG | MOR106 in combination with topical corticosteroids | moderate to severe atopic dermatitis | Phase II trial initiated enrolling 60 subjects |
| Forbius | AVID100 | EGFR-overexpressing Triple Negative Breast Cancer (TNBC) | Phase IIa trial initiated enrolling 100 subjects |
| Evofem Biosciences, Inc. | Amphora | sexually transmitted bacterial infections | Phase IIb trial initiated enrolling more than 850 female subjects who had been treated for chlamydia or gonorrhea in the preceding four months |
| TaiGen Biotechnology Company, Limited | Furaprevir in combination with Yimitasvir | chronic hepatitis C | Phase III trial initiated enrolling 360 subjects with both cirrhotic and non-cirrhotic genotype 1 in China |
| GlycoMimetics, Inc. | uproleselan | Acute Myeloid Leukemia (AML) | Phase III trial initiated enrolling 250 subjects with relapsed/refractory AML |
| Mallinckrodt, plc | Acthar Gel (Repository Corticotropin Injection) | Systemic Lupus Erythematosus (lupus, SLE) | Phase IV trial initiated enrolling 172 subjects with persistently active SLE |
| Beckman Coulter | Early Sepsis Indicator | sepsis | 510(k) clearance granted by the FDA |
| TELA Bio, Inc. | Restella Reconstructive BioScaffolds | reconstructive surgery | 510(k) clearance granted by the FDA |
| Repro-Med Systems, Inc. | HIgh-Flo Super26 Subcutaneous Needle Sets | subcutaneous infusion of medications | 510(k) clearance granted by the FDA |
| Akorn, Inc. | Fluticasone Propionate Nasal Spray | temporary relief of hay fever and other upper respiratory allergies in adult and pediatric subjects 4 years of age and older | ANDA approval granted by the FDA |
| Akorn, Inc. | Loteprednol Etabonate Ophthalmic Suspension, 0.5% | post-operative inflammation following ocular surgery | ANDA approval granted by the FDA |
| Moleculin Biotech, Inc. | Annamycin | relapsed or refractory acute myeloid leukemia (AML) | Fast Track designation granted by the FDA |
| GENFIT | elafibranor | Primary Biliary Cholangitis (PBC) in adult subjects with inadequate response to ursodeoxycholic acid (UDCA) | Breakthrough Therapy designation granted by the FDA |
| Viela Bio | inebilizumab | neuromyelitis optica spectrum disorder (NMOSD | Breakthrough Therapy designation granted by the FDA |
| Knopp Biosciences, LLC | dexpramipexole | hypereosinophilic syndrome (HES) | Orphan Drug designation granted by the FDA |
| NeuroSigma, Inc. | Monarch eTNS System (Monarch) | attention deficit hyperactivity disorder (ADHD) | Clearance to market granted by the FDA |
| BAROnova, Inc. | TransPyloric Shuttle (TPS) Device | obesity | Approval granted by the FDA |
| Boston Scientific Corporation | LOTUS Edge Aortic Valve System | severe aortic stenosis | Approval granted by the FDA |
| AbbVie | SKYRIZI (risankizumab-rzaa) | moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy | Approval granted by the FDA |
| Merck | KEYTRUDA in combination with Inlyta (axitinib) | advanced renal cell carcinoma (RCC) | Approval granted by the FDA |
| Teva Pharmaceutical Industries Ltd. | generic naloxone hydrochloride nasal spray | opioid overdose | Approval granted by the FDA |
Upcoming Events
-
25Apr
-
26Apr
-
27Apr
-
17May
-
21May
